Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7819394 | 1.00 | CYP3A4 (0.39) | CYP3A4HDAC1HDAC8HDAC4TGM2 | |
| SCHEMBL2238823 | 1.00 | CYP3A4 (0.39) | CYP3A4HDAC1HDAC8HDAC4TGM2 | |
| SCHEMBL3829153 | 0.92 | CYP3A4 (0.41) | CYP3A4HDAC1HDAC8HDAC4CTSB | |
| SCHEMBL13610255 | 0.90 | CYP3A4 (0.39) | CYP3A4HDAC1HDAC8HDAC4 | |
| SCHEMBL14586252 | 0.90 | HDAC1 (0.35) | CYP3A4HDAC1HDAC8HDAC4TGM2 | |
| SCHEMBL15747003 | 0.89 | HDAC1 (0.39) | CYP3A4HDAC1HDAC8HDAC4ITGB3 | |
| SCHEMBL10254350 | 0.89 | HDAC1 (0.39) | CYP3A4HDAC1HDAC8HDAC4ITGB3 | |
| SCHEMBL13783718 | 0.89 | HDAC1 (0.39) | CYP3A4HDAC1HDAC8HDAC4ITGB3 | |
| SCHEMBL1943013 | 0.89 | HDAC1 (0.39) | CYP3A4HDAC1HDAC8HDAC4ITGB3 | |
| SCHEMBL13610589 | 0.89 | HDAC1 (0.37) | CYP3A4HDAC1HDAC8HDAC4ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285773-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-19 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285773-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | CYP3A4 379/4885HDAC1 1626/4885HDAC8 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.